Biotech Values

[poorgradstudent]

I believe success in either one of these (both could fail obviously) could drive ARRY towards an EXEL-type valuation.

I don't want to make this about EXEL versus ARRY because I think it's more a conversation about company prospects and strategies rather than a battle of tickers.

But I will note that a few years ago when EXEL didn't interest me at all, many of the EXEL bulls were forwarding arguments that EXEL has so many drugs in the early pipeline and that any of those could hit for the jackpot! Others can correct me, but for a while EXEL was just accumulating failed early stage candidates left and right.

This might be a variation of the "bird in the hand" proverb, but sometimes the cumulative value of multiple shots on goal is not as large as one hopes.